Jafron Biomedical Co (300529.SZ) Stock Price
Jafron Biomedical Co Price
Revenue has compounded at 18.1% per year over the past 14 years to 2.01 B CNY. Earnings per share have grown at 15.0% per year over the last 14 years. Jafron Biomedical Co's net margin stands at 26.5%, down from 44.7% several years earlier. Jafron Biomedical Co currently offers a dividend yield of about 4.08%. The payout ratio is around 119% of earnings. The dividend has grown at 28.8% per year over the past 8 years. Analysts set a median price target of 25.59 CNY, implying 30.6% above the current price. Of 6 analysts, 5 rate the stock a buy — an overall Buy consensus.
Jafron Biomedical Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Jafron Biomedical Co business model & stock analysis
Frequently asked questions about Jafron Biomedical Co
Analysts currently set an average price target of 25.59 CNY for the Jafron Biomedical Co stock (median: 25.59 CNY), implying +30.6 % versus the latest price. The consensus is based on 6 analyst ratings.
6 analysts currently rate the Jafron Biomedical Co stock: 5 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Jafron Biomedical Co to generate revenue of 2.12 B CNY and earnings per share of 0.80 CNY.
Converted at the current exchange rate, the Jafron Biomedical Co share trades at 2.61 EUR (19.60 CNY).
The Jafron Biomedical Co share (300529.SZ) is listed on 1 stock exchanges, including: Shenzhen (300529.SZ).
The expected revenue of Jafron Biomedical Co is 2.12 B CNY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Jafron Biomedical Co is 632.72 M CNY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Jafron Biomedical Co is currently 24.59. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Jafron Biomedical Co stock.
The price-to-sales ratio (P/S) of Jafron Biomedical Co is currently 7.34. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Jafron Biomedical Co stock.
The Eulerpool Quality Score for Jafron Biomedical Co is 6/10.
The ISIN of Jafron Biomedical Co is CNE100002995. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Jafron Biomedical Co is 300529.SZ. The ticker symbol is used to trade Jafron Biomedical Co shares on the stock exchange.
Jafron Biomedical Co stock
Jafron Biomedical Co Peer Group
Jafron Biomedical Co Ticker
Jafron Biomedical Co FIGI
All fundamentals and in-depth analysis of Jafron Biomedical Co
Our stock analysis for Jafron Biomedical Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Jafron Biomedical Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.